Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Theodosia, Maina"'
Autor:
Panagiotis Kanellopoulos, Adam Mattsson, Ayman Abouzayed, Karim Obeid, Berthold A. Nock, Vladimir Tolmachev, Theodosia Maina, Anna Orlova
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-19 (2024)
Abstract Background The gastrin-releasing peptide receptor (GRPR) has been extensively studied as a biomolecular target for peptide-based radiotheranostics. However, the lack of metabolic stability and the rapid clearance of peptide radioligands, inc
Externí odkaz:
https://doaj.org/article/637e1155b147456f8a59fd7e94ba6862
Autor:
Maria Bibika, Panagiotis Kanellopoulos, Maritina Rouchota, George Loudos, Berthold A. Nock, Eric P. Krenning, Theodosia Maina
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1223 (2024)
Background: The concept of radiotheranostics relies on the overexpression of a biomolecular target on malignant cells to direct diagnostic/therapeutic radionuclide-carriers specifically to cancer lesions. The concomitant expression of more than one t
Externí odkaz:
https://doaj.org/article/95e76b12426f4ce9b6e24d4e6a8838e3
Autor:
Karim Obeid, Panagiotis Kanellopoulos, Ayman Abouzayed, Adam Mattsson, Vladimir Tolmachev, Berthold A. Nock, Theodosia Maina, Anna Orlova
Publikováno v:
Pharmaceutics, Vol 16, Iss 4, p 513 (2024)
Gastrin-releasing peptide receptor (GRPR)-antagonists have served as motifs in the development of theranostic radioligands for prostate cancer. Our efforts have been focused on the development of radiolabeled RM26 (H-DPhe6–Gln7–Trp8–Ala9–Val1
Externí odkaz:
https://doaj.org/article/76e700bb020b4623bb32b8e8e73fddd6
Autor:
Xabier Guarrochena, Panagiotis Kanellopoulos, Anna Stingeder, Lisa-Maria Rečnik, Irene V. J. Feiner, Marie Brandt, Wolfgang Kandioller, Theodosia Maina, Berthold A. Nock, Thomas L. Mindt
Publikováno v:
Pharmaceutics, Vol 16, Iss 3, p 392 (2024)
The use of metabolically stabilized, radiolabeled somatostatin (SST) analogs ([68Ga]Ga/[177Lu]Lu-DOTA-TATE/TOC/NOC) is well established in nuclear medicine. Despite the pivotal role of these radioligands in the diagnosis and therapy of neuroendocrine
Externí odkaz:
https://doaj.org/article/4ef1c7ad573d4fd6a7e508de73634328
Autor:
Aikaterini Tatsi, Theodosia Maina, Beatrice Waser, Eric P. Krenning, Marion de Jong, Jean Claude Reubi, Paul Cordopatis, Berthold A. Nock
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 3, p 1921 (2024)
The overexpression of one or more somatostatin receptors (SST1–5R) in human tumors has provided an opportunity for diagnosis and therapy with somatostatin-like radionuclide carriers. The application of “pansomatostatin” analogs is expected to b
Externí odkaz:
https://doaj.org/article/aeccb9c1811f4343bdfb2d9b5dd9a2ea
Autor:
Panagiotis Kanellopoulos, Berthold A. Nock, Maritina Rouchota, George Loudos, Eric P. Krenning, Theodosia Maina
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 21, p 15541 (2023)
Radiolabeled neurotensin analogs have been developed as candidates for theranostic use against neurotensin subtype 1 receptor (NTS1R)-expressing cancer. However, their fast degradation by two major peptidases, neprilysin (NEP) and angiotensin-convert
Externí odkaz:
https://doaj.org/article/8d502d0281e345b6b710116cfc0846db
Publikováno v:
Pharmaceutics, Vol 15, Iss 8, p 2092 (2023)
The neurotensin subtype 1 receptor (NTS1R) is overexpressed in a number of human tumors, thereby representing a valid target for cancer theranostics with radiolabeled neurotensin (NT) analogs like [99mTc]Tc-DT1 (DT1, N4-Gly7-NT(8-13)). Thus far, the
Externí odkaz:
https://doaj.org/article/3463a33f5dd0475b8b34fef879e407fa
Autor:
Ayman Abouzayed, Panagiotis Kanellopoulos, Alisa Gorislav, Vladimir Tolmachev, Theodosia Maina, Berthold A. Nock, Anna Orlova
Publikováno v:
Biomolecules, Vol 13, Iss 7, p 1134 (2023)
Radiolabeled gastrin-releasing peptide receptor (GRPR) antagonists have shown great promise for the theranostics of prostate cancer; however, their suboptimal metabolic stability leaves room for improvements. It was recently shown that the replacemen
Externí odkaz:
https://doaj.org/article/79181012fada4a63b12426352b6477b3
Publikováno v:
Pharmaceuticals, Vol 16, Iss 5, p 674 (2023)
The clinical success of radiolabeled somatostatin analogs in the diagnosis and therapy—“theranostics”—of tumors expressing the somatostatin subtype 2 receptor (SST2R) has paved the way for the development of a broader panel of peptide radioli
Externí odkaz:
https://doaj.org/article/f87d45c9955f4d469d77903ab3f51fcc
Autor:
Berthold A. Nock, Panagiotis Kanellopoulos, Euy Sung Moon, Maritina Rouchota, George Loudos, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Prashant Mishra, Parvind Sheokand, Frank Roesch, Theodosia Maina
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 776 (2023)
Aiming to expand the application of the SST2R-antagonist LM4 (DPhe-c[DCys-4Pal-DAph(Cbm)-Lys-Thr-Cys]-DTyr-NH2) beyond [68Ga]Ga-DATA5m-LM4 PET/CT (DATA5m, (6-pentanoic acid)-6-(amino)methy-1,4-diazepinetriacetate), we now introduce AAZTA5-LM4 (AAZTA5
Externí odkaz:
https://doaj.org/article/2f0690fde7c64c7fa0a01549ebc2a9b7